 TopNews New Zealand | Heart Failure Drug Promising in Phase III Trial MedPage Today A novel agent for treating acute heart failure met one of its two primary endpoints in reducing dyspnea, but which one has not yet been divulged, according to a statement from drug maker Novartis. One of the primary endpoints of the phase III RELAX-AHF ... Novartis Announces Top Line Results For Phase 3 Trial Of New Acute Heart ... Novartis's drug reduces heart failure deaths: study Results from Novartis Phase III study show that RLX030 reduced deaths in ... |
